Cetirizine hydrochloride - Generic Drug Details

What are the generic sources for cetirizine hydrochloride and what is the scope of patent protection?

Cetirizine hydrochloride is the generic ingredient in sixteen branded drugs marketed by Apotex, Aurobindo Pharma Ltd, Bionpharma, Catalent, Onesource Specialty, Harrow Eye, JDP, Actavis Mid Atlantic, Amneal Pharms, Apozeal Pharms, Bajaj, Chartwell Molecular, Lannett Co Inc, Padagis Us, Pharm Assoc, Ranbaxy Labs Ltd, Taro, Teva Pharms, Wockhardt, Aurobindo Pharma, Chartwell Rx, Cypress Pharm, Hetero Labs Ltd Iii, Perrigo R And D, Quagen, Tris Pharma Inc, Kenvue Brands, J And J Consumer Inc, Sun Pharm Inds Inc, Jubilant Generics, Novel Labs Inc, Sandoz, Sun Pharm, Regcon Holdings, Aiping Pharm Inc, Amneal Pharms Ny, Apotex Inc, Cipla Ltd, Contract Pharmacal, Dr Reddys Labs Ltd, Glenmark Pharms Inc, Granules, Heritage Pharma, Marksans Pharma, Mylan, Orbion Pharms, Pld Acquisitions, Sun Pharm Inds Ltd, Torrent Pharms Llc, Unichem, Unique, Ivax Sub Teva Pharms, and Ppi-dac, and is included in seventy-eight NDAs. There are nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Cetirizine hydrochloride has thirty patent family members in eight countries.

There are twelve drug master file entries for cetirizine hydrochloride. One hundred and sixty suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for cetirizine hydrochloride

International Patents:	30
US Patents:	9
Tradenames:	16
Applicants:	53
NDAs:	78
Drug Master File Entries:	12
Finished Product Suppliers / Packagers:	160
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Patent Applications:	6,288
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for cetirizine hydrochloride
What excipients (inactive ingredients) are in cetirizine hydrochloride?	cetirizine hydrochloride excipients list
DailyMed Link:	cetirizine hydrochloride at DailyMed

Recent Clinical Trials for cetirizine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Phayao	NA
Pengfei Qiu	NA
Shandong New Time Pharmaceutical Co., LTD	PHASE3

See all cetirizine hydrochloride clinical trials

Generic filers with tentative approvals for CETIRIZINE HYDROCHLORIDE

Applicant	Application No.	Strength	Dosage Form
		5MG/5ML	SOLUTION;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for cetirizine hydrochloride

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

Medical Subject Heading (MeSH) Categories for cetirizine hydrochloride

Anti-Allergic Agents

Histamine H1 Antagonists, Non-Sedating

Anatomical Therapeutic Chemical (ATC) Classes for cetirizine hydrochloride

R06AE	Piperazine derivatives
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for CETIRIZINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYRTEC	Syrup	cetirizine hydrochloride	5 mg/5 mL	020346	1	2007-03-19
CHILDREN'S ZYRTEC HIVES RELIEF	Chewable Tablets	cetirizine hydrochloride	5 mg and 10 mg	021621		2005-03-25

US Patents and Regulatory Information for cetirizine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ranbaxy Labs Ltd	CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	SOLUTION;ORAL	090183-002	Apr 24, 2008		DISCN	No	No
Unique	CETIRIZINE HYDROCHLORIDE HIVES	cetirizine hydrochloride	TABLET;ORAL	077829-002	Aug 26, 2009		OTC	No	Yes
Apozeal Pharms	CETIRIZINE HYDROCHLORIDE	cetirizine hydrochloride	SOLUTION;ORAL	078870-001	Apr 27, 2009	AA	RX	No	No
Contract Pharmacal	CETIRIZINE HYDROCHLORIDE ALLERGY	cetirizine hydrochloride	TABLET;ORAL	076047-002	Dec 27, 2007		OTC	No	No
Ranbaxy Labs Ltd	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF	cetirizine hydrochloride	SOLUTION;ORAL	090183-001	Apr 24, 2008		DISCN	No	No

Expired US Patents for cetirizine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
J And J Consumer Inc	ZYRTEC	cetirizine hydrochloride	SOLUTION;ORAL	020346-001	Sep 27, 1996	4,525,358*PED
Kenvue Brands	CHILDREN'S ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET, CHEWABLE;ORAL	021621-003	Nov 16, 2007	6,455,533
Kenvue Brands	CHILDREN'S ZYRTEC HIVES RELIEF	cetirizine hydrochloride	TABLET, CHEWABLE;ORAL	021621-006	Nov 16, 2007	6,455,533
Kenvue Brands	CHILDREN'S ZYRTEC HIVES RELIEF	cetirizine hydrochloride	TABLET, CHEWABLE;ORAL	021621-005	Nov 16, 2007	6,455,533
Kenvue Brands	CHILDREN'S ZYRTEC ALLERGY	cetirizine hydrochloride	TABLET, CHEWABLE;ORAL	021621-004	Nov 16, 2007	6,455,533

International Patents for cetirizine hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	2020117544	セチリジンの眼科用製剤および使用方法 (OPHTHALMOLOGIC PREPARATION OF CETIRIZINE AND METHODS OF USE)
Japan	6033677
European Patent Office	2408453	FORMULATIONS OPHTALMIQUES DE CÉTIRIZINE ET PROCÉDÉS D'UTILISATION (OPHTHALMIC FORMULATIONS OF CETIRIZINE AND METHODS OF USE)
Japan	2013522312
European Patent Office	2547340

Supplementary Protection Certificates for cetirizine hydrochloride

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0058146	2001C/045	Belgium		PRODUCT NAME: DICHLORHYDRATE DE LEVOCETIRIZINE; NAT RER. NO/DATE: 194 IS 90 F3 20011022; FIRST REG.: DE 49903.00.00 20010103
0663828	C300085	Netherlands		PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103

Market Dynamics and Financial Trajectory for Cetirizine Hydrochloride

Last updated: February 19, 2026

What Is the Current Market Size and Growth Path?

Cetirizine hydrochloride, a second-generation antihistamine used to treat allergic rhinitis and chronic urticaria, is a mature drug with broad global penetration. The global antihistamine market, valued at approximately $3.2 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 4.6% from 2023 to 2028 [1].

Within this segment, cetirizine's market share dominates, accounting for an estimated 35%, driven by its safety profile and availability in generic forms. Its revenue contribution in this space approximates $1.1 billion annually.

How Do Regulatory and Patent Factors Impact Market Dynamics?

Cetirizine was developed and marketed in the 1980s. Several key patent expirations occurred in the late 2000s, transitioning the drug from patented to generic status. This shift in patent protection led to increased price competition and volume growth.

Generic manufacturers account for roughly 80% of global cetirizine sales, pressuring originator firms to reduce prices. Current patents cover formulations, manufacturing processes, and delivery devices. Most of these patents expired by 2010, with some biosimilar equivalents entering specific markets since 2015.

Potential future patent filings involve novel formulations—such as sustained-release versions or combination products—aimed at differentiating offerings. These might temporarily impact market competition, but existing legal expirations keep price pressure high.

What Are Key Market Drivers and Restraints?

Primary drivers include:

• Rising prevalence of allergies globally, especially in urbanized regions.
• Increasing awareness and availability of over-the-counter (OTC) formulations.
• Expansion into emerging markets with large population bases.

Key restraints involve:

• Market saturation in developed countries.
• Competitive pricing from generic manufacturers.
• The advent of newer antihistamines with improved efficacy or fewer side effects.

How Does Pricing and Revenue Projection Evolve?

Average retail prices for cetirizine in developed markets decline approximately 10-15% annually since patent expiry, driven by generics. The global revenue for cetirizine is projected to stabilize around $1 billion annually over the next 5 years, assuming no significant market disruptions.

Sales volumes are expected to increase modestly, around 3-4% CAGR, mainly attributed to growth in emerging markets like India and Brazil. In these regions, increased healthcare access fuels demand for affordable allergy medications.

What Are Market Trends and Innovation Opportunities?

Despite being a mature drug, opportunities include:

• Development of combination therapies, e.g., cetirizine with decongestants.
• Novel delivery systems, such as sustained-release tablets.
• Focused formulations for children and elderly populations.

However, the core molecule's patent protection remains expired in most markets, limiting exclusivity-driven revenue growth.

What Is the Financial Outlook for Stakeholders?

For pharmaceutical companies:

• Generic firms benefit from high-volume, low-margin sales.
• Innovator companies focus on line extensions or formulations, with limited revenue expansion post-patent expiry.
• R&D investments into new antihistamines or alternative allergy treatments are relatively high compared to returns from cetirizine.

Market players forecast revenue stability, with slight growth prospects limited by generic competition and market saturation.

Summary Table: Key Market Data for Cetirizine Hydrochloride (2023-2028)

Metric	Value	Source
Global antihistamine market	$3.2 billion (2022)	[1]
Cetirizine market share	35% of antihistamine segment	Estimated
Annual revenue (cetirizine)	~$1.1 billion	Estimated
CAGR (2023-2028)	4.6%	[1]
Price decline (since patent expiry)	10-15% annually	Industry reports
Emerging market growth	6-8% CAGR	Market analyses

---

Key Takeaways

• Cetirizine hydrochloride holds a dominant position in the antihistamine market, with stable revenues driven by volume growth in emerging markets.
• Patent expirations have led to increased generic competition, reducing prices and profit margins.
• The market is saturated in developed countries; growth prospects rely on expanding access in emerging economies.
• Innovation focuses on new formulations and combination therapies; core molecule sales remain steady but limited.
• Stakeholders should monitor regulatory changes, biosimilar entries, and formulation innovations for future revenue opportunities.

---

FAQs

1. What factors could disrupt cetirizine's market stability?
Patent challenges, regulatory changes, or the approval of superior allergy medications could impact sales. Additionally, increased self-medication and OTC accessibility could reduce formal market sales.

2. How does cetirizine compare to other antihistamines in efficacy?
Cetirizine has a rapid onset of action and longer duration than first-generation antihistamines. It has a better safety profile than older options but faces competition from newer agents with fewer sedative effects.

3. Are biosimilars influencing cetirizine's market?
Biosimilars are not currently significant for cetirizine as it is a small molecule. However, similar generics or novel formulations could influence sales dynamics akin to biosimilar effects.

4. What regional markets are most promising for growth?
India and Brazil exhibit high growth potential due to increasing healthcare access and population size. Asia-Pacific, in general, is a key region for expansion.

5. How might future formulation innovations impact revenue?
Sustained-release tablets and combination products could command premium pricing, but patent protections are typically limited. The primary impact would be through niche or specialty markets.

---

References

[1] MarketWatch. (2023). Global antihistamine market size, growth, and forecast. MarketWatch.
[2] IQVIA. (2022). Pharmaceutical market analytics report. IQVIA.
[3] Statista. (2022). Over-the-counter allergy medications global sales. Statista.

Note: All projections and data are estimates based on publicly available reports and market analyses as of early 2023.